Will LYB report Q1 2026 Adjusted EBITDA of $850M or more?
Current Prediction
Why This Question Matters
The first hard-data check on the cycle. Q1 earnings (late April 2026) is the imminent post-data-cutoff catalyst. $850M represents a meaningful sequential step-up from the $660M Q4 trough that would validate the cycle-turning framework. A miss below $850M keeps LYB in extended-trough territory and strengthens the Myth Meter GAP_EXISTS read that the +40% rally is narrative-driven rather than earnings-driven. High uncertainty because Winter Storm Fern may have produced a transient boost that obscures the underlying trajectory.
Prediction Distribution
Individual Predictions(9 runs)
Q4 2025 was $660M (trough). $850M is a +29% sequential step-up — near the top end of typical trough-phase sequential improvement without a specific one-time contribution. Key tailwinds: (1) Winter Storm Fern PE price realization (potentially material), (2) VEP/CIP momentum, (3) possible Taiwan land gain (~$360M) if booked in Q1 with Adjusted EBITDA treatment — but management typically excludes one-time gains. Headwinds: European O&P -$61M drag continues, naphtha/ethane spreads still normalizing, management's 'longest trough' framing. If Taiwan gain is IN Adjusted EBITDA, probability ~55-60%; if excluded (more likely), probability ~35-40%. Weight toward exclusion given Fugazi Filter QUESTIONABLE: management has incentive to be transparent about one-time. Settle 0.40.
Management 'longest trough' framing + European O&P drag + seasonal Q1 softness argue for modest sequential improvement ($660M → $720-800M range most likely). $850M requires above-consensus cycle-turning confirmation. Winter Storm Fern impact is real but bounded by duration and geographic scope. Taiwan gain uncertain in classification. Cyclical trough Q1-to-Q1 sequential improvements at +10-20% are typical; +29% is above typical. 0.38 captures the positioning: not out of reach but also not the base case.
Counterweight view: Q1 2026 likely has substantial Winter Storm Fern tailwind not captured in $660M Q4. VEP and CIP continue delivering. Q1 is also first post-$1.5B pre-funding quarter; Taiwan timing unclear. If management classifies Taiwan gain as Adjusted EBITDA-eligible (consistent with prior-period presentation), probability jumps to 65%+. Markets often anchor expectations to sequential improvement; $850M is plausible if management is executing into the cycle turn. Settle 0.45 reflecting meaningful but not base case.
Key signal: management framing is 'longest trough in industry history' — revealed preference against Q1 cycle-turning print. Q1 seasonality in petchem is typically soft (post-holiday destocking, pre-spring demand). +29% sequential from Q4 ($660M) to Q1 ($850M) would be exceptional. Winter Storm Fern is a real but time-limited tailwind. Taiwan gain likely excluded from Adjusted EBITDA. Base case: Q1 $720-800M. Probability Q1 >=$850M ~30-40%. Settle 0.35.
Slightly more constructive view: Winter Storm Fern likely drove meaningful PE price realization for 2-4 weeks of Q1; even a 1-week PE uplift at +15-20% prices could contribute $50-100M to segment EBITDA. Combined with VEP ($1.1B running rate, +$100M over target) + CIP + Taiwan (if included) + weak-$USD effects, there are plausible paths to $850M even if not the base case. Balanced at 0.42.
Balance tailwinds (Winter Storm Fern, VEP, possibly Taiwan) against headwinds (European drag, Q1 seasonality, management 'longest trough' framing). Central tendency Q1 ~$740M; $850M is ~1 std dev above. Probability ~35-40%.
Q4 $660M → Q1 $850M is +29% sequential. Winter Storm Fern + VEP/CIP + possible Taiwan gain create plausible path but not base case. 0.40 central.
Cycle trough + management 'longest trough' argues against cycle-turning print. $850M is plausible but 35-40%.
Winter Storm Fern + VEP momentum could produce a surprise Q1. 40-45% probability captures upside without anchoring on base case.
Resolution Criteria
Resolves YES if LYB's reported Q1 2026 Adjusted EBITDA (as defined in the earnings press release reconciliation, consistent with prior-period presentation, including Taiwan land gain contribution only if treated as non-one-time by management) is $850M or higher. Resolves NO if reported Adjusted EBITDA is below $850M, or if LYB changes its Adjusted EBITDA definition materially (in which case, use the closest comparable prior-period metric).
Resolution Source
LYB Q1 2026 earnings release (expected late April 2026)
Source Trigger
Q1 2026 earnings release (late April 2026) — PE price realization, segment EBITDA, 2026 guidance refresh
Full multi-lens equity analysis